EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSMPUG00000000691
Gene Symbol: SCN9A
2 Cross references
110 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSMPUG00000011210
Gene Symbol: SLC10A2
4 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSMPUG00000003349
Gene Symbol: SLC18A2
2 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSMPUG00000012895
Gene Symbol: SLC22A11
2 Cross references
885 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSMPUG00000012842
Gene Symbol: SLC22A12
2 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSMPUG00000013551
Gene Symbol: SLC22A6
4 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSMPUG00000013544
Gene Symbol: SLC22A8
2 Cross references
310 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMPUG00000012621
Gene Symbol: SLC29A1
2 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSMPUG00000012749
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSMPUG00000011343
Gene Symbol: SLC5A2
2 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSMPUG00000017170
Gene Symbol: SLC6A1
2 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSMPUG00000003413
Gene Symbol: SLC6A2
4 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).